143 related articles for article (PubMed ID: 23039022)
1. Access to medicines, market failure and market intervention: a tale of two regimes.
Williams OD
Glob Public Health; 2012; 7 Suppl 2():S127-43. PubMed ID: 23039022
[TBL] [Abstract][Full Text] [Related]
2. Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K; Srivastava S
Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
4. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
5. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
[TBL] [Abstract][Full Text] [Related]
6. Solution to contentious issue of Article 31(f) of TRIPS agreement.
Janodia MD; Sreedhar D; Ligade VS; Udupa N
Indian J Med Res; 2008 Jul; 128(1):84-5; author reply 85-86. PubMed ID: 18820365
[No Abstract] [Full Text] [Related]
7. The morally uncomfortable global drug gap.
Cohen-Kohler JC
Clin Pharmacol Ther; 2007 Nov; 82(5):610-4. PubMed ID: 17898710
[TBL] [Abstract][Full Text] [Related]
8. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
Jung Y; Kwon S
Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
[TBL] [Abstract][Full Text] [Related]
10. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC; Forman L; Lipkus N
Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
[TBL] [Abstract][Full Text] [Related]
11. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
12. Access to essential medicines: a Hobbesian social contract approach.
Ashcroft RE
Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical pricing in the developing world: issues of access to medicines.
Mrazek MF
Expert Rev Pharmacoecon Outcomes Res; 2002 Feb; 2(1):43-50. PubMed ID: 19807429
[TBL] [Abstract][Full Text] [Related]
14. "Rights" and wrongs: what utility for the right to health in reforming trade rules on medicines?
Forman L
Health Hum Rights; 2008; 10(2):37-52. PubMed ID: 20845858
[TBL] [Abstract][Full Text] [Related]
15. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
16. New frontier of AIDS activism: international trade rules and global access to medicines. Interview by John S. James.
Sawyer E
AIDS Treat News; 1999 Apr; (No 317):1, 5-8. PubMed ID: 11366992
[TBL] [Abstract][Full Text] [Related]
17. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
Kuek V; Phillips K; Kohler JC
Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
[TBL] [Abstract][Full Text] [Related]
18. Implications of bilateral free trade agreements on access to medicines.
Correa CM
Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
[TBL] [Abstract][Full Text] [Related]
19. The role of intellectual property rights in treatment access: challenges and solutions.
't Hoen E; Passarelli CA
Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
[TBL] [Abstract][Full Text] [Related]
20. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
Rai AK
Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
